HIGHLIGHTS
SUMMARY
Innovative drugs the authors can find chimeric antigen receptor T_cells (CAR-T_cells), bispecific antibodies (BsAbs), and antibody drug conjugates (ADC). CARs are genetically engineered receptors expressed by T_cells (or any cells), thus conferring them specific properties, e_g, anti-tumor activity. In 2012, a seven-year-old patient suffering from acute lymphoid leukemia successfully received the first anti-CD19 CAR-T_cell. CAR-T_cells are now reserved for highly advanced MM, but they should soon benefit patients in early lines of therapy. CAR-T_cells are usually well tolerated or at least their toxicity is now considered . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.